Clinical Trial: Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography

Brief Summary: The aim of this study was to evaluate safety and therapeutic response to micropulse diode 810nm laser treatment in patients with chronic central serous chorioretinopathy.

Detailed Summary: Most of the cases of central serous chorioretinopathy (CSC) recur spontaneously within three months of disease. After 3 months without resolution of acute CSC or in chronic CSC, continuous wave laser photocoagulation or photodynamic therapy should be considered. Direct threshold continuous photocoagulation treatment can shorten the duration of the serous detachment, but it is not appropriate for juxtafoveal or subfoveal leakage point.Subvisible photocoagulation potentially localizes and decreases chorioretinal thermic burn. Subthreshold diode micropulse (SDM) laser using a 810nm diode laser may spare the damage to the neural retina by raising the temperature of the RPE to just below the protein-denaturation threshold so that the thermal wave that reaches the neural retina is insufficient to cause neither damage nor clinically visible end-point. This therapeutic laser modality offers the possibility to minimize the iatrogenic retinal lesion.
Sponsor: Federal University of São Paulo

Current Primary Outcome: Best corrected visual acuity [ Time Frame: 6 months ]

Best corrected visual acuity measured by ETDRS chart at baseline, 1, 3, 6, 9 and 12 months


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Macular subretinal fluid [ Time Frame: 6 months ]
    Central macular thickness measured by spectral-domain optical coherence tomography at baseline, 1, 3, 6, 9 and 12 months
  • Leakage at fluorescein angiogram [ Time Frame: 6 months ]
    Leakage at fluorescein angiogram evaluated at baseline, 3, 6, 9 and 12 months


Original Secondary Outcome: Same as current

Information By: Federal University of São Paulo

Dates:
Date Received: March 29, 2011
Date Started: November 2008
Date Completion:
Last Updated: March 30, 2011
Last Verified: March 2011